APPLICATION NUMBER:
22428Orig1s000

CHEMISTRY REVIEW(S)
NDA 22-428

Moxifloxacin Alternative Formulation (AF)
Ophthalmic Solution, 0.5%

Alcon Pharmaceuticals Ltd.

Lin Qi
Division of Anti-Infective and Ophthalmology Product
# Table of Contents

**Chemistry Review Data Sheet** ........................................................................................................3

**The Executive Summary** .................................................................................................................8

I. Recommendations .................................................................................................................................8
   A. Recommendation and Conclusion on Approvability ........................................................................8
   B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk 
      Management Steps, if Approvable .................................................................................................. 8

II. Summary of Chemistry Assessments .................................................................................................8
   A. Description of the Drug Product(s) and Drug Substance(s) ............................................................. 8
   B. Description of How the Drug Product is Intended to be Used.......................................................... 9
   C. Basis for Approvability or Not-Approval Recommendation ............................................................ 9

III. Administrative ...................................................................................................................................10
   A. Reviewer’s Signature ....................................................................................................................... 10
   B. Endorsement Block ....................................................................................................................... 10
   C. CC Block ....................................................................................................................................... 10
Chemistry Review Data Sheet

1. NDA 22-428

2. REVIEW #: 2

3. REVIEW DATE: October 1, 2009

4. REVIEWER: Lin Qi

5. PREVIOUS DOCUMENTS:

<table>
<thead>
<tr>
<th>Previous Documents</th>
<th>Document Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

6. SUBMISSION(S) BEING REVIEWED:

<table>
<thead>
<tr>
<th>Submission(s) Reviewed</th>
<th>Document Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Original</td>
<td>12/15/2008</td>
</tr>
<tr>
<td>Amendment</td>
<td>2/11/2009</td>
</tr>
<tr>
<td>Amendment</td>
<td>6/11/2009</td>
</tr>
</tbody>
</table>

7. NAME & ADDRESS OF APPLICANT:

   Name: Alcon Pharmaceuticals Ltd.
   Route des Arsenaux 41
   1700 Fribourg
   Switzerland
   US Agent:
   Representative: Alcon Research Ltd.
   6201 South Freeway
   Fort Worth, TX 76134-2099
   Telephone: 817-568-6494 (Karen Lankow)
8. DRUG PRODUCT NAME/CODE/TYPEx:
   a) Proprietary Name: Moxifloxacin Alternative Formulation (AF) Ophthalmic Solution
   b) Non-Proprietary Name (USAN): Moxifloxacin Hydrochloride
   c) Code Name/# (ONDC only):
      Company or Laboratory Code: AL-15469A (Alcon), BAY 12-8039 (Bayer)
   d) Chem. Type/Submission Priority (ONDC only):
      - Chem. Type: 3
      - Submission Priority: S

9. LEGAL BASIS FOR SUBMISSION: 505 (b)(1)

10. PHARMACOL. CATEGORY: Antibacterial agent

11. DOSAGE FORM: Ophthalmic solution

12. STRENGTH/POTENCY: 0.5% as base

13. ROUTE OF ADMINISTRATION: Topical/ocular, one drop in affected eye
    two times a day

14. Rx/OTC DISPENSED: _X__Rx     ___OTC

15. **SPOTS (SPECIAL PRODUCTS ON-LINE TRACKING SYSTEM):**
    — SPOTS product – Form Completed
    — _X_ Not a SPOTS product
16. CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOLECULAR WEIGHT:

Chemical Name(s):
1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolol [3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic acid, monohydrochloride or (4aS-cis)-1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(octahydro-6H-pyrrolol [3,4-b]pyridin-6-yl)-4-oxo-3-quinolinecarboxylic acid, monohydrochloride

Chemical structure:

![Chemical Structure](image)

Molecular Formula: $C_{21}H_{24}FN_3O_4\cdot HCl$

Relative Molecular Mass: 437.9; 401.4 (base)

Recommended International Nonproprietary Name (INN): Moxifloxacin

Compendial Name (USAN): Moxifloxacin Hydrochloride

Other Non-Proprietary Name(s):
1-Cyclopropyl-7-[(S,S)-2,8-diazabicyclo[4.3.0] non-8-yl]-6-fluoro-8-methoxy-1,4 -dihydro 4-oxo-3-quinoline carboxylic acid, monohydrochloride

Chemical Abstracts Service (CAS) Registry Number
186826-86-8 (salt)
151096-09-2 (base)
17. RELATED/SUPPORTING DOCUMENTS:

A. DMFs:

<table>
<thead>
<tr>
<th>DMF #</th>
<th>TYPE</th>
<th>HOLDER</th>
<th>ITEM REFERENCED</th>
<th>CODE</th>
<th>STATUS</th>
<th>DATE REVIEW COMPLETED</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>III</td>
<td>4</td>
<td>N/A</td>
<td>Not reviewed</td>
<td></td>
<td>LOA: 5/20/08</td>
<td></td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>1</td>
<td>Adequate</td>
<td>8/25/09</td>
<td></td>
<td>LOA: 8/11/08</td>
<td></td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>4</td>
<td>N/A</td>
<td>Not reviewed</td>
<td></td>
<td>LOA: 8/6/08</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1 Action codes for DMF Table:
1 – DMF Reviewed.
Other codes indicate why the DMF was not reviewed, as follows:
2 – Type 1 DMF
3 – Reviewed previously and no revision since last review
4 – Sufficient information in application
5 – Authority to reference not granted
6 – DMF not available
7 – Other (explain under "Comments")

2 Adequate, Inadequate, or N/A (There is enough data in the application, therefore the DMF did not need to be reviewed)

B. Other Documents:

<table>
<thead>
<tr>
<th>DOCUMENT</th>
<th>APPLICATION NUMBER</th>
<th>DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA 21-085</td>
<td>NDA 21-085</td>
<td>Same drug substance, LOA dated 8/27/08</td>
</tr>
<tr>
<td>NDA 21-598</td>
<td>NDA 21-598</td>
<td>Same drug substance, Alcon</td>
</tr>
</tbody>
</table>
18. STATUS:

**ONDC:**

<table>
<thead>
<tr>
<th>CONSULTS/ CMC RELATED REVIEWS</th>
<th>RECOMMENDATION</th>
<th>DATE</th>
<th>REVIEWER</th>
</tr>
</thead>
<tbody>
<tr>
<td>EES</td>
<td>Acceptable</td>
<td>Oct 1, 2009</td>
<td>Marisa Stock</td>
</tr>
<tr>
<td>Methods Validation</td>
<td>Acceptable</td>
<td>Jul 30, 2009</td>
<td>Lin Qi</td>
</tr>
<tr>
<td>Microbiology</td>
<td>Acceptable</td>
<td>Sep 30, 2009</td>
<td>Robert Mello</td>
</tr>
</tbody>
</table>
The Chemistry Review for NDA 22-428

The Executive Summary

I. Recommendations

A. Recommendation and Conclusion on Approvability

This application is recommended for approval from the quality perspective.

B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable

N/A

II. Summary of Chemistry Assessments

A. Description of the Drug Product(s) and Drug Substance(s)

The drug substance, moxifloxacin hydrochloride, is a slightly yellow to yellow powder or crystalline solid. Its solubility in water is \((b)(4)\). Moxifloxacin hydrochloride has a pKa1 of \((b)(4)\) and \((b)(4)\). It has a partition coefficient of \((b)(4)\) and \((b)(4)\). Moxifloxacin hydrochloride is used as the drug substance in the approved NDA 21-085 and NDA 21-598. Moxifloxacin hydrochloride is manufactured and supplied by Bayer AG, Wuppertal, Germany. Drug substance manufacturing and control information is referenced in NDA 21-085 and NDA 21-598.

The drug product, Vigamox AF (moxifloxacin hydrochloride ophthalmic solution) 0.5%, is a sterile, \((b)(4)\) ophthalmic solution containing 0.545% w/v moxifloxacin hydrochloride, equivalent to 0.5% moxifloxacin. The product is greenish yellow solution with an osmolality of 300-370 mOsm/kg and a pH of approximately 7.4 \((b)(4)\). This product is developed using the same drug substance and for the same indication as Vigamox (moxifloxacin HCl ophthalmic solution) 0.5% as base (NDA 21-598). However, this proposed formulation has been modified with \((b)(4)\) with similar efficacy to marketed Vigamox but with a less frequent dosing regimen from TID to BID. The excipients used in the proposed product include sodium chloride, xanthan gum, boric acid, sorbitol, tyloxapol, purified water, and hydrochloride acid and/or sodium hydroxide to adjust pH (See page 14 of quality review #1 for composition). No \((b)(4)\) is used in the proposed formulation because Moxifloxacin AF ophthalmic solution has been observed to maintain adequate \((b)(4)\) to meet USP \((b)(4)\) effectiveness requirements in the absence of a \((b)(4)\) agent.
The product will be packaged with a labeled fill volume of 1 mL and 3 mL (Trade size) in a 4 mL natural, low density polyethylene (LDPE) bottle with a polyethylene (LDPE) natural dispensing plug and a tan polypropylene (PP) closure. The drug product will be manufactured and tested at Alcon Research, Ltd., Fort Worth, TX (See page 23 of quality review #1 for the proposed regulatory specification for the drug product).

B. Description of How the Drug Product is Intended to be Used

The proposed indication for this product is to treat bacterial conjunctivitis. The proposed dosing regimen is “Instill 1 drop in the affected eye(s) 2 times daily for 7 days.”

The proposed shelf-life is 24 months for the 3 mL trade size product at the proposed storage condition, 2°C-25°C (36°F-77°F).

C. Basis for Approvability or Not-Approval Recommendation

In quality review #1, this application is recommended for approval pending a satisfactory quality microbiological review and an “Acceptable” recommendation from the Office of Compliance on the GMP status of facilities. An “Acceptable” recommendation was provided by the Office of Compliance in September 30, 2009 (See Attachment). Dr. Robert J Mello recommended approval in his product quality microbiological review dated September 29, 2009 with the following two comments:

“Quality Microbiological Comments: (The following are not deficiencies but are comments, only, to be provided to the Applicant.)

1. The specification for bacterial endotoxin (NMT \( \text{(b)} \)) while similar to some other Alcon topical ophthalmic drug products containing xanthan gum, is higher than the expected limit of \( \text{(b)} \) for such drug products. The applicant is advised, as part of the product’s continual process improvement life cycle, to establish a program to lower the acceptance criteria to NMT \( \text{(b)} \).
III. Administrative

A. Reviewer’s Signature

{See signature and date in DARRTS.}

Lin Qi, Ph.D.

_____________________________  ________________
Review Chemist                   Date

Norman Schmuff, Ph.D.

______________________________  ________________
Branch Chief                    Date

B. Endorsement Block

Filed in DARRTS.

C. CC Block

See CC list filed in DARRTS.
<table>
<thead>
<tr>
<th>Application Type/Number</th>
<th>Submission Type/Number</th>
<th>Submitter Name</th>
<th>Product Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA-22428</td>
<td>ORIG-1</td>
<td>ALCON PHARMACEUTICALS LTD</td>
<td>MOXIFLOXACIN ALTERNATIVE FORMULATION OP</td>
</tr>
</tbody>
</table>

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

LIN QI
10/05/2009

NORMAN R SCHMUFF
10/05/2009
NDA 22-428

Moxifloxacin Alternative Formulation (AF)
Ophthalmic Solution, 0.5%

Alcon Pharmaceuticals Ltd.

Lin Qi
Division of Anti-Infected and Ophthalmology Product
Table of Contents

Table of Contents .....................................................................................................2
Chemistry Review Data Sheet.................................................................................3
The Executive Summary .........................................................................................8

I. Recommendations.............................................................................................................8
   A. Recommendation and Conclusion on Approvability .........................................................8
   B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable .........................................................8

II. Summary of Chemistry Assessments.............................................................................8
   A. Description of the Drug Product(s) and Drug Substance(s) .............................................8
   B. Description of How the Drug Product is Intended to be Used .......................................9
   C. Basis for Approvability or Not-Approval Recommendation ........................................9

III. Administrative.............................................................................................................10
   A. Reviewer’s Signature ........................................................................................................10
   B. Endorsement Block ........................................................................................................10
   C. CC Block ........................................................................................................................10

Chemistry Assessment ...........................................................................................11

I. Review Of Common Technical Document-Quality (Ctd-Q) Module 3.2: Body Of Data....11
   S DRUG SUBSTANCE [Name, Manufacturer] .....................................................................11
   P DRUG PRODUCT [Name, Dosage form] .........................................................................14
   A APPENDICES .............................................................................................................42
   R REGIONAL INFORMATION .........................................................................................42

II. Review Of Common Technical Document-Quality (Ctd-Q) Module 1 ...........................42
   A. Labeling & Package Insert ..............................................................................................42
   B. Environmental Assessment Or Claim Of Categorical Exclusion .....................................43

III. List Of Deficiencies To Be Communicated ..................................................................43
Chemistry Review Data Sheet

1. NDA 22-428

2. REVIEW #: 1

3. REVIEW DATE: Aug 5, 2009

4. REVIEWER: Lin Qi

5. PREVIOUS DOCUMENTS:

<table>
<thead>
<tr>
<th>Previous Documents</th>
<th>Document Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Original</td>
<td>12/15/2008</td>
</tr>
<tr>
<td>Amendment</td>
<td>2/11/2009</td>
</tr>
<tr>
<td>Amendment</td>
<td>6/11/2009</td>
</tr>
</tbody>
</table>

6. SUBMISSION(S) BEING REVIEWED:

7. NAME & ADDRESS OF APPLICANT:

   Name: Alcon Pharmaceuticals Ltd.
   Route des Arsenaux 41
   1700 Fribourg
   Switzerland
   US Agent: Alcon Research Ltd.
   6201 South Freeway
   Fort Worth, TX 76134-2099
   Representative: 817-568-6494 (Karen Lankow)
8. DRUG PRODUCT NAME/CODE/TYPE:
   a) Proprietary Name: Moxifloxacin Alternative Formulation (AF) Ophthalmic Solution
   b) Non-Proprietary Name (USAN): Moxifloxacin Hydrochloride
   c) Code Name/# (ONDC only):
      Company or Laboratory Code: AL-15469A (Alcon), BAY 12-8039 (Bayer)
   d) Chem. Type/Submission Priority (ONDC only):
      • Chem. Type: 3
      • Submission Priority: S

9. LEGAL BASIS FOR SUBMISSION: 505 (b)(1)

10. PHARMACOL. CATEGORY: Antibacterial agent

11. DOSAGE FORM: Ophthalmic solution

12. STRENGTH/POTENCY: 0.5% as base

13. ROUTE OF ADMINISTRATION: Topical/ocular, one drop in affected eye two times a day

14. Rx/OTC DISPENSED: _X__Rx ___OTC

15. SPOTS (SPECIAL PRODUCTS ON-LINE TRACKING SYSTEM):
   SPOTS product – Form Completed
   _X__Not a SPOTS product
16. CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOLECULAR WEIGHT:

Chemical Name(s):
1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic acid, monohydrochloride or (4aS-cis)-1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-3-quinolinecarboxylic acid, monohydrochloride

Chemical structure:

![Chemical structure diagram]

Molecular Formula: \( C_{21}H_{24}FN_3O_4 \cdot HCl \)

Relative Molecular Mass: 437.9; 401.4 (base)

Recommended International Nonproprietary Name (INN): Moxifloxacin

Compendial Name (USAN): Moxifloxacin Hydrochloride

Other Non-Proprietary Name(s):
1-Cyclopropyl-7-(S,S)-2,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinoline carboxylic acid, monohydrochloride

Chemical Abstracts Service (CAS) Registry Number
186826-86-8 (salt)
151096-09-2 (base)
17. RELATED/SUPPORTING DOCUMENTS:

A. DMFs:

<table>
<thead>
<tr>
<th>DMF #</th>
<th>TYPE</th>
<th>HOLDER</th>
<th>ITEM REFERENCED</th>
<th>CODE</th>
<th>STATUS</th>
<th>DATE REVIEW COMPLETED</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>III</td>
<td>4</td>
<td>N/A</td>
<td>Not reviewed</td>
<td>4</td>
<td>N/A</td>
<td>Not reviewed</td>
<td>LOA: 5/20/08</td>
</tr>
<tr>
<td>III</td>
<td>1</td>
<td>Adequate</td>
<td>8/25/09</td>
<td>1</td>
<td>Adequate</td>
<td>8/25/09</td>
<td>LOA: 8/11/08</td>
</tr>
<tr>
<td>III</td>
<td>4</td>
<td>N/A</td>
<td>Not reviewed</td>
<td>4</td>
<td>N/A</td>
<td>Not reviewed</td>
<td>LOA: 8/6/08</td>
</tr>
</tbody>
</table>

1 Action codes for DMF Table:
1 – DMF Reviewed.
Other codes indicate why the DMF was not reviewed, as follows:
2 – Type 1 DMF
3 – Reviewed previously and no revision since last review
4 – Sufficient information in application
5 – Authority to reference not granted
6 – DMF not available
7 – Other (explain under "Comments")

2 Adequate, Inadequate, or N/A (There is enough data in the application, therefore the DMF did not need to be reviewed)

B. Other Documents:

<table>
<thead>
<tr>
<th>DOCUMENT</th>
<th>APPLICATION NUMBER</th>
<th>DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA 21-085</td>
<td>NDA 21-085</td>
<td>Same drug substance, LOA dated 8/27/08</td>
</tr>
<tr>
<td>NDA 21-598</td>
<td>NDA 21-598</td>
<td>Same drug substance, Alcon</td>
</tr>
</tbody>
</table>
18. STATUS:

<table>
<thead>
<tr>
<th>CONSULTS/ CMC RELATED REVIEWS</th>
<th>RECOMMENDATION</th>
<th>DATE</th>
<th>REVIEWER</th>
</tr>
</thead>
<tbody>
<tr>
<td>EES</td>
<td>Pending</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methods Validation</td>
<td>Acceptable</td>
<td>July 30, 2009</td>
<td>Lin Qi</td>
</tr>
<tr>
<td>Microbiology</td>
<td>Pending</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
The Chemistry Review for NDA 22-428

The Executive Summary

I. Recommendations

A. Recommendation and Conclusion on Approvability

This application is not recommended for approval as there are pending issues related to the GMP status of facilities and a satisfactory quality microbiological review. All other drug product quality (CMC) issues are satisfactory.

B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable

N/A

II. Summary of Chemistry Assessments

A. Description of the Drug Product(s) and Drug Substance(s)

The drug substance, moxifloxacin hydrochloride, is a slightly yellow to yellow powder or crystalline solid. Its solubility in water is (b) (4) Moxifloxacin hydrochloride has a pKa1 of (b) (4) and pKa2 of (b) (4). It has a partition coefficient of log PO/W of (b) (4) and (b) (4). Moxifloxacin hydrochloride is used as the drug substance in the approved NDA 21-085 and NDA 21-598. Moxifloxacin hydrochloride is manufactured and supplied by Bayer AG, Wuppertal, Germany. Drug substance manufacturing and control information is referenced in NDA 21-085 and NDA 21-598.

The drug product, Vigamox AF (moxifloxacin hydrochloride ophthalmic solution) 0.5%, is a sterile (b) (4) ophthalmic solution containing 0.545% w/v moxifloxacin hydrochloride, equivalent to 0.5% moxifloxacin. The product is greenish yellow solution with an osmolality of 300-370 mOsm/kg and a pH of approximately 7.4 (b) (4). This product is developed using the same drug substance and for the same indication as Vigamox (moxifloxacin HCl ophthalmic solution) 0.5% as base (NDA 21-598). However, this proposed formulation has been modified with (b) (4) similar efficacy to marketed Vigamox but with a less frequent dosing regimen from TID to BID. The excipients used in the proposed product include sodium chloride, xanthan gum, boric acid, sorbitol, tyloxapol, purified water, and hydrochloride acid and/or sodium hydroxide to adjust pH (See page 14 for composition). No (b) (4) is used in the proposed formulation because Moxifloxacin AF ophthalmic solution has been observed to maintain adequate effectiveness in the absence of a (b) (4) agent.
The product will be packaged with a labeled fill volume of 1 mL (Sample size) and 3 mL (Trade size) in a 4 mL natural, low density polyethylene (LDPE) bottle with a polyethylene (LDPE) natural dispensing plug and a tan polypropylene (PP) closure. The drug product will be manufactured and tested at Alcon Research, Ltd., Fort Worth, TX (See page 23 for the proposed regulatory specification for the drug product).

B. Description of How the Drug Product is Intended to be Used

The proposed indication for this product is to treat bacterial conjunctivitis. The proposed dosing regimen is “Instill 1 drop in the affected eye(s) 2 times daily for 7 days.”

The proposed shelf-life is 24 months for the 3 mL trade size product at the proposed storage condition, 2°C-25°C (36°F-77°F).

C. Basis for Approvability or Not-Approval Recommendation

The purpose of current application is to develop a formulation similar to Vigamox with the to provide similar efficacy to marketed Vigamox with reduced dosing regimen. Both drug products have the same concentration (0.5%) of the active ingredient moxifloxacin.

The applicant proposed acceptance criteria for the release and stability tests based on pharmacopoeial standards, batch release data, and the results from the accelerated and long-term stability studies on three primary stability batches for trade size of moxifloxacin AF ophthalmic solution. The acceptance criteria are consistent with those for Vigamox (approved NDA 21-598) except for the acceptance criteria for “Product” and “Total Impurities”. The proposed acceptance criterion for “Product” is decreased from [b] for Vigamox to [b] for current product because this impurity has not been observed to date (through 104 weeks) in stability studies with moxifloxacin AF ophthalmic solution. The proposed acceptance criterion for “Total Impurities” was also decreased from [b] for Vigamox to [b] for the current product. The acceptance criteria are adequately justified. The tests and acceptance criteria for bacterial endotoxins, sterility, and effectiveness will be evaluated by the quality microbiological reviewer.

The stability data for the primary lots of moxifloxacin AF ophthalmic solution are available up to 104 weeks at 25°C/40% RH. All test results through the proposed
for samples at 25°C/40% RH meet the proposed regulatory specification. Therefore the proposed shelf-life is 24 months for the 3 mL trade size product.

This application is recommended for approval pending a satisfactory quality microbiological review and an “Acceptable” recommendation from the Office of Compliance on the GMP status of facilities.

III. Administrative

A. Reviewer’s Signature

See signature in DARRTS.

B. Endorsement Block

ChemistName/Date: Same date as draft review
ChemistryTeamLeaderName/Date
ProjectManagerName/Date

C. CC Block
<table>
<thead>
<tr>
<th>Linked Applications</th>
<th>Submission Type/Number</th>
<th>Sponsor Name</th>
<th>Drug Name / Subject</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA 22428</td>
<td>ORIG 1</td>
<td>ALCON PHARMACEUTICA LS LTD</td>
<td>MOXIFLOXACIN ALTERNATIVE FORMULATION OP</td>
</tr>
<tr>
<td>NDA 22428</td>
<td>ORIG 1</td>
<td>ALCON PHARMACEUTICA LS LTD</td>
<td>MOXIFLOXACIN ALTERNATIVE FORMULATION OP</td>
</tr>
</tbody>
</table>

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

LIN QI
08/24/2009

NORMAN R SCHMUFF
08/26/2009
Summary and Critical Issues:

**Summary**

In general, this NDA, 3S, dated December 12, 2008, is straightforward. The product is a multi-use ophthalmic solution formulated with moxifloxacin HCl. This is a 505(b)(1) NDA, submitted in CTD format and was accepted as a standard NDA. No priority name was identified in the NDA.

A microbiology consult was submitted by the OND PM, Lori Gorski and Dr. Robert Mello was assigned. Ms. Gorski stated she will submit the labeling consult to DDMAC.

The drug substance is manufactured by Bayer Healthcare AG, Wuppertal, Germany. Moxifloxacin has An LOA was submitted, referencing the synthesis, controls and stability information to NDA 21-085. This is the same source as Alcon’s Vigamox, moxifloxacin ophthalmic solution product.

The drug product with pH of 7.4 is manufactured, packaged, labeled, release and stability tested at Alcon Research Ltd, Fort Worth, Texas. The pH and osmolality are higher for this product than for Vigamox.

The drug product is stored in Alcon’s natural LDPE ‘Drop-tainer’ bottle, natural LDPE plug, and a tan LDPE cap with pressure sensitive label and shrink band around the neck and cap. The container and are described in DMF and the is in DMF the same as Vigamox. No manufacturer is mentioned in this NDA for the bottle, plug and cap.
whereas Vigamox specified the manufacturers for the container closure. is the sterilization technique for the container closure used in both NDAs.

The average drop is claimed to be whereas Vigamox claimed for its trade size. Vigamox trade size is 3 mL in 6 mL container; this product trade size is 3 mL in 4 mL bottle, and the professional size is 1 mL in 4 mL bottle.

Two new degradants, not mentioned for Vigamox, are listed in the drug product specification.

104 weeks, 3 batches each for both professional and trade sizes, stability data at 25C/40%RH and 26 weeks at 40C/25%RH were submitted. Upright and horizontal positions were studied. 156 weeks at refrigerator storage were also evaluated. Freeze thaw and light studies were provided. Expiration dating period is claimed to be 24 months for the trade size.

**Critical issues for review**

- All tests should be evaluated for meaningful conditions and criteria. The endotoxin level is expressed on a per dose basis that converts to EU per mL. This is higher than products approved in the past. Micro will have to evaluate.
- The effectiveness test is missing in the drug product specification. Micro should be alerted to evaluate.
- Draft labels were submitted. The applicant should provide mock-up of the labels for evaluation.
- The information appears to be missing. Reviewer should follow up.
• The drop size is larger than the Vigamox product. Reviewer should check that number of drops per bottle is adequate for patient use period.

Comments for 74-Day Letter
None recommended.

D. Review, Comments and Recommendation:

Acceptable for filing. No team review is recommended. A single reviewer can review this NDA due to the fairly straightforward issues. Dr. Lin Qi has been assigned to review this NDA.

___Linda Ng, Ph.D._________  May 19, 2009
Pharmaceutical Assessment Lead  Date

___Norman Schmuff, Ph.D.______
Branch Chief  ____________________

Cc: OND PM LGorshi
ONDQA PM JDavid
Appendix 1. Composition of the Drug Product

<table>
<thead>
<tr>
<th>Component</th>
<th>Percent W/V</th>
<th>Compendial Designation</th>
<th>Purpose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moxifloxacin Hydrochloride</td>
<td>0.545 b</td>
<td>Non-Compendial c</td>
<td>Active</td>
</tr>
<tr>
<td>Xanthan Gum</td>
<td>(b) (4)</td>
<td>NF</td>
<td></td>
</tr>
<tr>
<td>Sodium Chloride</td>
<td></td>
<td>USP</td>
<td></td>
</tr>
<tr>
<td>Boric Acid</td>
<td></td>
<td>NF</td>
<td></td>
</tr>
<tr>
<td>Sorbitol</td>
<td></td>
<td>NF</td>
<td></td>
</tr>
<tr>
<td>Tyloxapol</td>
<td></td>
<td>USP</td>
<td></td>
</tr>
<tr>
<td>Hydrochloric Acid and/or Sodium Hydroxide</td>
<td>Adjust pH to 7.4</td>
<td>NF</td>
<td>pH Adjusters</td>
</tr>
<tr>
<td>Purified Water</td>
<td>(b) (4)</td>
<td>USP</td>
<td></td>
</tr>
</tbody>
</table>

* FID = formulation identification number
* 0.545\% moxifloxacin hydrochloride is equivalent to 0.5% moxifloxacin base
* Although moxifloxacin hydrochloride has a Ph. Eur. Monograph, Alcon will continue to test the material to the specifications approved for VIGAMOX (NDA 21-598).
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Linda Ng
5/19/2009 03:59:40 PM
CHEMIST

Norman Schmuff
6/8/2009 10:59:04 PM
CHEMIST